Controlled delivery of TLR3 agonists in structural polymeric devices

Patent metadata

Field	Value
Publication number	US-9821045-B2
Application number	US-201615135216-A
Country	US
Kind code	B2
Filing date	Apr 21, 2016
Priority date	Feb 13, 2008
Publication date	Nov 21, 2017
Grant date	Nov 21, 2017

Abstract

The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents.

First claim

What is claimed is:

1. A device comprising a polymeric structure composition, a tumor antigen, and a TLR3 agonist, wherein said TLR3 agonist comprises condensed polyinosine-polycytidylic acid (poly I:C) cationic nanoparticles, said condensed poly I:C cationic nanoparticles being formed by mixing said poly I:C with a polycation comprising positively charged amine groups at a charge ratio resulting in positively charged condensates and an average particle size of 98-545 nm.

2. The device of claim 1 , further comprising a TLR9 agonist.

3. The device of claim 1 , wherein said TLR3 agonist is present at a concentration effective to induce production of interleukin-12 (IL-12) by dendritic cells.

4. The device of claim 1 , wherein when the device is implanted in a subject, 200-400 ng/mL of IL-12 is produced at the site of implantation.

5. The device of claim 1 , wherein the condensed poly (I:C) cationic nanoparticle comprises PEI-poly(I:C).

6. The device of claim 2 , wherein the TLR9 agonist comprises a cytosine-guanosine oligonucleotide (CpG-ODN) or condensed CpG-ODN.

7. The device of claim 1 , wherein the polymeric structure composition comprises poly-lactide-co-glycolide (PLG).

8. The device of claim 2 , wherein the polymeric structure composition comprises poly-lactide-co-glycolide (PLG).

9. The device of claim 1 , further comprising pathogen associated molecular patterns (PAMPs).

10. The device of claim 2 , wherein the TLR9 agonist comprises a nucleic acid.

11. The device of claim 10 , wherein the nucleic acid comprises a cytosine-guanosine oligonucleotide (CpG-ODN) or a PEI-CpG-ODN.

12. The device of claim 1 , further comprising a recruitment composition.

13. The device of claim 12 , wherein the recruitment composition comprises granulocyte macrophage colony stimulating factor (GM-CSF), Flt3L, or CCL20.

14. The device of claim 13 , wherein the device comprises 0.5 μg to 500 μg of GM-CSF.

15. The device of claim 13 , wherein the recruitment composition comprises encapsulated GM-CSF.

16. The device of claim 1 , wherein the tumor antigen comprises a tumor lysate, purified protein tumor antigen, or synthesized tumor antigen.

17. The device of claim 1 , comprising 100 μg-10,000 μg of tumor antigen.

18. The device of claim 1 , wherein the tumor antigen is a lung cancer tumor antigen.

19. The device of claim 1 , wherein the tumor antigen comprises an antigen from a cancer selected from the group consisting of a central nervous system (CNS) cancer, CNS Germ Cell tumor, Leukemia, Multiple Myeloma, Renal Cancer, Malignant Glioma, breast cancer, squamous cell carcinoma, ovarian carcinoma, prostate cancer, Kaposi's sarcoma, colon cancer, adenocarcinoma, testicular cancer, hepatocellular carcinoma, Synovial sarcoma, and Medulloblastoma.

20. The device of claim 2 , wherein the tumor antigen comprises an antigen from a cancer selected from the group consisting of a central nervous system (CNS) cancer, CNS Germ Cell tumor, Leukemia, Multiple Myeloma, Renal Cancer, Malignant Glioma, breast cancer, squamous cell carcinoma, ovarian carcinoma, prostate cancer, Kaposi's sarcoma, colon cancer, adenocarcinoma, testicular cancer, hepatocellular carcinoma, Synovial sarcoma, and Medulloblastoma.

21. The device of claim 2 , further comprising a recruitment composition.

22. The device of claim 21 , wherein the recruitment composition comprises granulocyte macrophage colony stimulating factor (GM-CSF), Flt3L, or CCL20.

23. The device of claim 2 , wherein the tumor antigen comprises a tumor lysate, purified protein tumor antigen, or synthesized tumor antigen.

24. The device of claim 1 , wherein said polymeric structure composition is anionic and said condensed poly I:C cationic nanoparticles are electrostatically immobilized on said anionic polymeric structure composition of said device.

25. The device of claim 2 , wherein said polymeric structure composition is anionic and said condensed poly I:C cationic nanoparticles are electrostatically immobilized on said anionic polymeric structure composition of said device.

26. The device of claim 1 , wherein said charge ratio comprises an amino-phosphate charge ratio of 3, 4, 7, or 15.

27. The device of claim 2 , wherein said charge ratio comprises an amino-phosphate charge ratio of 3, 4, 7, or 15.

Assignees

• Harvard College
• Dana Farber Cancer Inst Inc
• Dana-Farber Cancer Inst

Inventors

• Ali Omar Abdel-Rahman
• Dranoff Glenn
• Mooney David J

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K2039/55588

  Adjuvants of undefined constitution · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title